,
Bonnefoi, Hervé
MacGrogan, Gaetan
Poncet, Coralie
Iggo, Richard
Pommeret, Fanny
Grellety, Thomas
Larsimont, Denis
Bécette, Véronique
Kerdraon, Olivier
Bibeau, Frédéric
Ghnassia, Jean-Pierre
Picquenot, Jean-Michel
Thomas, Jeremy
Tille, Jean-Christophe
Slaets, Leen
Bodmer, Alexandre
Bergh, Jonas
Cameron, David
Funding for this research was provided by:
European Organisation for Research and Treatment of Cancer
Article History
Received: 13 July 2018
Revised: 9 February 2019
Accepted: 20 February 2019
First Online: 22 March 2019
Competing interests
: The authors declare that they have no competing interests.
: The trial was registered with ClinicalTrials.gov number NCT00017095 and approved by national and/or local ethics committees in all participating centres (Supplementary Table ). Before registration, all patients signed an informed consent for the trial and for mandatory p53 gene assessment on tumour samples. In addition, patients were asked to consent for optional biological research on their tumour samples. The study was performed in accordance with the Declaration of Helsinki.
: EORTC sponsored, designed and coordinated the trial. The funding sources had no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all the study data and the final responsibility for the decision to submit for publication. Trial design, conduct and analysis were done at the EORTC headquarters independently from all funding bodies.
: Data can be accessed through the EORTC data-sharing platform. Data request form is available on the EORTC website:
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).